13D Filing: Longwood Fund II, L.P. and Kalvista Pharmaceuticals Inc. (KALV)

Page 7 of 9 – SEC Filing


CUSIP No. 483497103 Page 7 of 10

Item 4. Purpose of Transaction.

Westphal and Aldrich, by virtue of their roles as the managers of LFII GP, may each be deemed to hold certain voting powers with respect to the reportable
securities owned by LFII. Except as otherwise described in this statement, the Reporting Persons do not have any present plans or proposals that relate to or would result in: (i) the acquisition by any person of additional securities of the
Issuer, or the disposition of securities of the Issuer; (ii) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (iii) a sale or transfer of a material
amount of assets of the Issuer or any of its subsidiaries; (iv) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing
vacancies on the board; (v) any material change in the present capitalization or dividend policy of the Issuer; (vi) any other material change in the Issuers business or corporate structure; (vii) changes in the Issuers
charter, by-laws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (viii) causing a class of securities of the Issuer to be de-listed from a national securities
exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (ix) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant
to Section 12(g)(4) of the Exchange Act; or (x) any action similar to any of those enumerated above.

Item 5. Interest in Securities of
the Issuer.

The information below is based on a total of 10,783,631 shares of Common Stock outstanding as of October 12, 2017, according to
information supplied by the Issuer.

(a) LFII beneficially owns 934,484shares of Common Stock, or approximately 8.7% of the Common Stock outstanding. LFII
GP, as the general partner of LFII, may be deemed to indirectly beneficially own the securities owned by LFII.

(b) The managers of LFII GP may be deemed
to share the power to vote or direct the voting of and to dispose or direct the disposition of the securities of the Issuer that are beneficially owned by LFII. Each such person disclaims beneficial ownership of all securities other than those he or
she owns directly, if any, or by virtue of his or her indirect pro rata interest, as a member of LFII GP, in the securities owned by LFII and such person may be deemed to have sole power to vote or direct the voting of and to dispose or direct the
disposition of the securities of the Issuer that are beneficially owned by LFII.

(c) Except as described in this statement, none of the Reporting Persons
has effected any transactions in the Common Stock in the 60 days prior to the date of this statement.

(d) Except as described in this statement, no person
has the power to direct the receipt of dividends on or the proceeds of sales of, the shares of Common Stock owned by the Reporting Persons.

(e) Not
applicable.

Follow Kalvista Pharmaceuticals Inc. (NASDAQ:KALV)